Alsulays Bader B, Kulkarni Vijay, Alshehri Sultan M, Almutairy Bjad K, Ashour Eman A, Morott Joseph T, Alshetaili Abdullah S, Park Jun-Bom, Tiwari Roshan V, Repka Michael A
a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA.
b Department of Pharmaceutics, College of Pharmacy , Prince Sattam Bin Abdulaziz University , Alkharj , Saudi Arabia.
Drug Dev Ind Pharm. 2017 May;43(5):789-796. doi: 10.1080/03639045.2016.1220567. Epub 2016 Aug 21.
The objective of this work was to use hot-melt extrusion (HME) technology to improve the physiochemical properties of lansoprazole (LNS) to prepare stable enteric coated LNS tablets. For the extrusion process, we chose Kollidon 12 PF (K12) polymeric matrix. Lutrol F 68 was selected as the plasticizer and magnesium oxide (MgO) as the alkalizer. With or without the alkalizer, LNS at 10% drug load was extruded with K12 and F68. LNS changed to the amorphous phase and showed better release compared to that of the pure crystalline drug. Inclusion of MgO improved LNS extrudability and release and resulted in over 80% drug release in the buffer stage. Hot-melt extruded LNS was physically and chemically stable after 12 months of storage. Both formulations were studied for compatibility with Eudragit L100-55. The optimized formulation was compressed into a tablet followed by coating process utilizing a pan coater using L100-55 as an enteric coating polymer. In a two-step dissolution study, the release profile of the enteric coated LNS tablets in the acidic stage was less than 10% of the LNS, while that in the buffer stage was more than 80%. Drug content analysis revealed the LNS content to be 97%, indicating the chemical stability of the enteric coated tablet after storage for six months. HME, which has not been previously used for LNS, is a valuable technique to reduce processing time in the manufacture of enteric coated formulations of an acid-sensitive active pharmaceutical ingredient as compared to the existing methods.
本研究的目的是利用热熔挤出(HME)技术改善兰索拉唑(LNS)的理化性质,以制备稳定的肠溶包衣LNS片剂。对于挤出工艺,我们选择了聚维酮12 PF(K12)聚合物基质。选择聚氧乙烯蓖麻油F 68作为增塑剂,氧化镁(MgO)作为碱化剂。在有或没有碱化剂的情况下,将载药量为10%的LNS与K12和F68一起挤出。LNS转变为非晶相,与纯结晶药物相比显示出更好的释放性能。加入MgO改善了LNS的可挤出性和释放性能,在缓冲阶段药物释放率超过80%。热熔挤出的LNS在储存12个月后物理和化学性质稳定。研究了两种配方与尤特奇L100-55的相容性。将优化后的配方压制成片剂,然后使用锅包衣机,以L100-55作为肠溶包衣聚合物进行包衣。在两步溶出度研究中,肠溶包衣LNS片剂在酸性阶段的释放率低于LNS的10%,而在缓冲阶段的释放率超过80%。药物含量分析显示LNS含量为97%,表明肠溶包衣片剂在储存六个月后的化学稳定性。与现有方法相比,HME此前未用于LNS,是一种在制备酸敏感活性药物成分的肠溶包衣制剂时减少加工时间的有价值技术。